CAR-T Cell Therapy for Leukemia from Mexico
CAR-T cell therapy consists of patient-derived T-cells that are genetically modified to express chimeric antigen receptors targeting CD19-positive cancer cells. This personalized immunotherapy is used to treat relapsed B-cell acute lymphoblastic leukemia and falls under tariff item 3002.51.00 as a cell therapy product.
Duty Rate — Mexico → Canada
0%
Import Tips
• Ensure the product is classified as a cell therapy product under 3002.51.00 and not as a vaccine or other biological product
• Provide documentation of the genetic modification and therapeutic use to CBSA
• Verify that the product meets Health Canada regulations for human cells and tissues